Dietary practices in glutaric aciduria type 1 over 16 years

J Hum Nutr Diet. 2012 Dec;25(6):514-9. doi: 10.1111/j.1365-277X.2012.01269.x. Epub 2012 Jul 30.

Abstract

Background: In glutaric aciduria type 1 (GA1), dietary treatment with emergency management (EM) is essential to prevent encephalopathic crisis (EC). In the present study, dietary practices were examined in a single UK centre without access to newborn screening.

Methods: Twenty GA1 patients (11 males, median age: 10.2 years, range 2.2-24.1 years) were evaluated. Nine presented without EC (median diagnosis age: 1.1 years, range 4 days to 8 years) and 11 with EC (median diagnosis age 10 months, range 6 months to 1.7 years). Dietary treatment, neurological outcome, anthropometry and biochemical/haematological markers were assessed.

Results: Diet treatment varied according to age of diagnosis and symptom severity. Four of six pre-encephalopathic children diagnosed before 2 years of age were treated with carnitine, protein restriction (medium l.2 g kg day(-1)) and lysine-free/low tryptophan protein substitute (PS) (medium dose: 1.6 g kg day(-1)). EM consisted of natural protein cessation and glucose polymer with PS delivered via an enteral feeding tube. Older children (>3 years) without EC were given carnitine and protein restriction, and seven of nine EC patients had PS via an enteral feeding tube. Clinical deterioration occurred in two patients without EC; one taking PS and protein restriction (with a second untreatable pathology) and one after protein restriction only. In patients presenting with EC, four died and one had some improvement in movement, with the rest remaining stable but with severe disability. Patients taking PS had better nutritional markers [serum vitamin B(12) (P < 0.001), albumin (P < 0.001), haemoglobin (P < 0.001) and essential plasma amino acids].

Conclusions: Early diagnosis of GA1 before EC is essential because PS and protein restriction with meticulous EM prevents EC. PS also improves nutritional status irrespective of clinical condition.

MeSH terms

  • Adolescent
  • Adult
  • Age Factors
  • Amino Acid Metabolism, Inborn Errors / complications
  • Amino Acid Metabolism, Inborn Errors / diagnosis
  • Amino Acid Metabolism, Inborn Errors / diet therapy*
  • Amino Acid Metabolism, Inborn Errors / mortality
  • Amino Acid Metabolism, Inborn Errors / therapy
  • Biomarkers / blood
  • Brain Diseases / etiology
  • Brain Diseases / prevention & control
  • Brain Diseases, Metabolic / complications
  • Brain Diseases, Metabolic / diagnosis
  • Brain Diseases, Metabolic / diet therapy*
  • Brain Diseases, Metabolic / mortality
  • Brain Diseases, Metabolic / therapy
  • Carnitine / therapeutic use
  • Child
  • Child, Preschool
  • Diet, Protein-Restricted*
  • Dietary Proteins* / adverse effects
  • Dietary Proteins* / therapeutic use
  • Dietetics / methods
  • Disabled Persons
  • Early Diagnosis
  • Enteral Nutrition
  • Female
  • Glucose / therapeutic use
  • Glutaryl-CoA Dehydrogenase / deficiency
  • Humans
  • Lysine / administration & dosage*
  • Lysine / adverse effects
  • Male
  • Practice Patterns, Physicians'*
  • Severity of Illness Index
  • Tryptophan / administration & dosage*
  • Tryptophan / adverse effects
  • United Kingdom / epidemiology
  • Young Adult

Substances

  • Biomarkers
  • Dietary Proteins
  • Tryptophan
  • Glutaryl-CoA Dehydrogenase
  • Glucose
  • Lysine
  • Carnitine

Supplementary concepts

  • Glutaric Acidemia I